INVENTIVA Cash and cash equivalents at €11.0 million, short-term2 deposits at €0.1million, and long-term deposit at €19.1 million3 as of March 31, 2024, compared to €26.9 million, €0.01 million and €9.0 million as of December 31, 2023, respectively. The fourth scheduled DMC meeting recommended to continue the NATiV3 Phase III clinical trial without modification of
Many billionaire investors are going all in on artificial intelligence (AI). That’s understandable. AI is quickly being integrated into businesses’ day-to-day operations. The leaders in the field could deliver outsized returns. However, there are other exciting investment opportunities out there. Consider Renaissance Technologies, a hedge fund headed by Jim Simons. The fund’s holdings feature several
Cbio A/S Cleanroom operator cutting tumor tissue Picture of Cbio cleanroom operator cutting tumor tissue for T-cell therapy production SØBORG, Denmark, April 12, 2024 (GLOBE NEWSWIRE) — Cbio A/S – Pioneering Next-Gen T-Cell Therapies for Solid Tumors, Unveils 2023 Financial Results and Company Updates. Ulrik Cordes, Founder & CEO of Cbio, stated: “2023 was another
OSE Immunotherapeutics Financial highlights €18.7 million available cash as of December 31st, 2023, not including the upcoming $48 million payment as part of the recent collaboration and license partnership (February 2024) with AbbVie1, nor the €5.8 million of R&D Tax credit, providing reinforced financial visibility until 2026. Proprietary clinical pipeline highlights Tedopi®, optimized epitope-based cancer vaccine:
Researchers are trialing a new type of targeted radiotherapy to treat secondary breast cancer tumors in the brain, thanks to new funding from Breast Cancer Now. Image Credit: Breast Cancer Now Secondary (or metastatic) breast cancer is when breast cancer spreads to other parts of the body. While it’s incurable, the disease can be treated,